

12/06/01

Express Mail Label No. EI74825560US

12-10-01

UTILITY PATENT APPLICATION TRANSMITTAL

(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

P01627

Total Pages in this Submission

166

TO THE ASSISTANT COMMISSIONER FOR PATENTS

Box Patent Application

Washington, D.C. 20231

Transmitted herewith for filing under 35 U.S.C. 111(a) and 37 C.F.R. 1.53(b) is a new utility patent application for an invention entitled:

POLY(2-OXAZOLINE) BIOMEDICAL DEVICES

and invented by:

Jay F. Kunzler; Yu Chin Lai; Joseph A. McGee; Paul L. Valint, Jr.If a **CONTINUATION APPLICATION**, check appropriate box and supply the requisite information:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Which is a:

Continuation Divisional Continuation-in-part (CIP) of prior application No.: _____

Enclosed are:

Application Elements1. Filing fee as calculated and transmitted as described below2. Specification having 12 pages and including the following:

- a. Descriptive Title of the Invention
- b. Cross References to Related Applications (if applicable)
- c. Statement Regarding Federally-sponsored Research/Development (if applicable)
- d. Reference to Microfiche Appendix (if applicable)
- e. Background of the Invention
- f. Brief Summary of the Invention
- g. Brief Description of the Drawings (if drawings filed)
- h. Detailed Description
- i. Claim(s) as Classified Below
- j. Abstract of the Disclosure

JCS 80 U.S. PTO

12/06/01

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.

P01627

Total Pages in this Submission

166

Application Elements (Continued)

3. Drawing(s) (when necessary as prescribed by 35 USC 113)
a. Formal Number of Sheets _____
b. Informal Number of Sheets _____

4. Oath or Declaration
a. Newly executed (original or copy) Unexecuted
b. Copy from a prior application (37 CFR 1.63(d)) (for continuation/divisional application only)
c. With Power of Attorney Without Power of Attorney
d. **DELETION OF INVENTOR(S)**
Signed statement attached deleting inventor(s) named in the prior application,
see 37 C.F.R. 1.63(d)(2) and 1.33(b).

5. Incorporation By Reference (usable if Box 4b is checked)
The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied
under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby
incorporated by reference therein.

6. Computer Program in Microfiche (Appendix)

7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all must be included)
a. Paper Copy
b. Computer Readable Copy (identical to computer copy)
c. Statement Verifying Identical Paper and Computer Readable Copy

Accompanying Application Parts

8. Assignment Papers (cover sheet & document(s))

9. 37 CFR 3.73(B) Statement (when there is an assignee)

10. English Translation Document (if applicable)

11. Information Disclosure Statement/PTO-1449 Copies of IDS Citations

12. Preliminary Amendment

13. Acknowledgment postcard

14. Certificate of Mailing
 First Class Express Mail (Specify Label No.): EI748257910US

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
P01627

Total Pages in this Submission
166

Acc mpanying Application Parts (Continued)

15. Certified Copy of Priority Document(s) *(if foreign priority is claimed)*

16. Additional Enclosures *(please identify below):*

Request That Application Not Be Published Pursuant To 35 U.S.C. 122(b)(2)

17. Pursuant to 35 U.S.C. 122(b)(2), Applicant hereby requests that this patent application not be published pursuant to 35 U.S.C. 122(b)(1). Applicant hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication of applications 18 months after filing of the application.

Warning

An applicant who makes a request not to publish, but who subsequently files in a foreign country or under a multilateral international agreement specified in 35 U.S.C. 122(b)(2)(B)(i), must notify the Director of such filing not later than 45 days after the date of the filing of such foreign or international application. A failure of the applicant to provide such notice within the prescribed period shall result in the application being regarded as abandoned, unless it is shown to the satisfaction of the Director that the delay in submitting the notice was unintentional.

UTILITY PATENT APPLICATION TRANSMITTAL
(Large Entity)

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Docket No.
P01627

Total Pages in this Submission
166

Fee Calculation and Transmittal

CLAIMS AS FILED

For	#Filed	#Allowed	#Extra	Rate	Fee
Total Claims	19	- 20 =	0	x \$18.00	\$0.00
Indep. Claims	1	- 3 =	0	x \$84.00	\$0.00
Multiple Dependent Claims (check if applicable) <input type="checkbox"/>					\$0.00
					BASIC FEE \$740.00
OTHER FEE (specify purpose) _____					\$0.00
					TOTAL FILING FEE \$740.00

A check in the amount of _____ to cover the filing fee is enclosed.
 The Commissioner is hereby authorized to charge and credit Deposit Account No. 02-1425 as described below. A duplicate copy of this sheet is enclosed.
 Charge the amount of \$740.00 as filing fee.
 Credit any overpayment.
 Charge any additional filing fees required under 37 C.F.R. 1.16 and 1.17.
 Charge the issue fee set in 37 C.F.R. 1.18 at the mailing of the Notice of Allowance, pursuant to 37 C.F.R. 1.311(b).



Signature

John E. Thomas
Registration No. 34,070
Bausch & Lomb Incorporated
One Bausch & Lomb Place
Rochester, New York 14604-2701
Telephone: 585/338-8969

Dated: December 6, 2001

cc:

CERTIFICATE OF MAILING BY "EXPRESS MAIL" (37 CFR 1.10)			Docket No.
Applicant(s): Jay F. Kunzler; Yu Chin Lai; Joseph A. McGee; Paul L. Valint, Jr.			P01627
Serial No.	Filing Date	Examiner	Group Art Unit
Not Yet Assigned	December 06, 2001	Not Yet Assigned	Not Yet Assigned

Invention: Poly(2-Oxazoline) Biomedical Devices

I hereby certify that this New Utility Patent Application and its Attachments is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to: U. S. Patent and Trademark Office, P O Box 2327, Box Patent Application, Arlington, VA 22202 on December 06, 2001.

Sharon L. Sechrist

(Typed or Printed Name of Person Mailing Correspondence)



(Signature of Person Mailing Correspondence)

EI748257910US

(“Express Mail” Mailing Label Number)

Note: Each paper must have its own certificate of mailing.